CHICAGO—Patients with recurrent high-grade serous or BRCA-dependent ovarian cancer responded well to a combination of two investigational drugs—the anti-angiogenic agent cediranib and the PARP-inhibitor olaparib—in a phase II study presented at the American Society of Clinical Oncology 2014 Annual Meeting. Lead study author Joyce Liu, MD, MPH, an instructor in medical oncology at Dana-Farber Cancer Institute in Boston, MA, told Oncology Times reporter Peter Goodwin about the theory behind this potentially synergistic combination of treatments and the clinical potential the findings hold out.
Abstract Number: LBA5500
J Clin Oncol 32:5s, 2014 (suppl; abstr LBA5500)
A randomized phase 2 trial comparing efficacy of the combination of the PARP inhibitor olaparib and the antiangiogenic cediranib against olaparib alone in recurrent platinum-sensitive ovarian cancer.

Loading more stuff…

Hmm…it looks like things are taking a while to load. Try again?

Loading videos…